Lucid Ultrasound System 1.1 Enhances the User Experience to Improve Usability and Efficiency
LOS ANGELES--(BUSINESS WIRE)--Neural Analytics Inc., a medical device company developing and commercializing technology to measure, diagnose and track brain health, today announced the latest system update for its next generation ultrasound device, the Lucid M1 Transcranial Doppler Ultrasound System™ (Lucid System). The Lucid System is an FDA cleared fully portable, all-in-one ultrasound system designed for measuring and displaying cerebral blood flow velocities and monitoring of patients with brain disorders.
“This launch has the potential to optimize patient care by enabling clinicians to quickly access critical brain health information with the option to save and archive data from our platform across the entire hospital network.”
“The launch of our latest system update further demonstrates our commitment to continually enhance our technology to better meet the needs of healthcare professionals and their patients,” said Leo Petrossian, Chief Executive Officer of Neural Analytics. “This launch has the potential to optimize patient care by enabling clinicians to quickly access critical brain health information with the option to save and archive data from our platform across the entire hospital network.”
The Lucid System uses a type of ultrasound called Trans Cranial Doppler to assess the brain’s blood vessels from outside the body. This analysis is non-invasive, can be performed in the physician’s office and can help the physician diagnose brain disorders, potentially eliminating the need for additional, more invasive tests. Many significant brain disorders are caused by blood flow disruption. The Lucid System is a battery operated medical grade tablet device designed to be moved easily throughout a medical facility in a range of settings that require the rapid assessment of blood flow in the brain to expedite treatment.
About Blood Flow Disorders
Each year, severe blood flow disorders affect more than 30 million people globally. Traumatic Brain Injury (TBI) and stroke contribute the most to the global disease burden for these disorders. Approximately 2.5 million people are affected by TBI each year in the United States with 14.8 million people affected globally. The cost of TBI care in the U.S. alone totals $77 billion annually and, reliable triage and timely treatment remains unavailable for a vast majority of these patients. Stroke affects about 16 million people and kill an estimated 5.7 million, with an annual U.S. healthcare cost of $104 billion.1,2,3,4
About Neural Analytics Inc.
Neural Analytics was founded in 2013 to create products and services to measure, diagnose and track brain health. They combine leading data science with cutting edge hardware to allow first responders and clinicians to accurately assess and monitor brain health issues. Their devices are designed to be portable, autonomous, reliable, and produce precise and objective physiological measurements for medical responder monitoring of neural disorders.
More information is available at http://www.neuralanalytics.com.
Sources:
1. Ganesalingam, J. Cost Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke. Stroke. 2015 Sep;46(9):2591-8. doi: 10.1161/STROKEAHA.115.009396. Epub 2015 Aug 6.
2. Saver, J. et. Al. Stent Retriever Thrombectomy after Intraveneous t-PA vs. t_PA alone in stroke. N Engl J Med 2015; 372:2285-2295
3. Ovbiagele, B. et. Al Forecasting the Future of Stroke in the United States. Stroke. 2013. http://stroke.ahajournals.org/content/44/8/2361.abstract,
4. Age Ageing (2009) 38 (1): 4-5.doi: 10.1093/ageing/afn282
Contacts
Neural Analytics Inc.
Henry Hewes, +1-949-239-2018
Global Vice President, Sales and Marketing
henry@neuralanalytics.com
